EICHORCondition: Liver Neoplasms · Postoperative Complications · Sponsor: First Affiliated Hospital, Sun Yat-Sen University
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
Liver resection is an important surgical treatment for patients with liver diseases. Despite advances in surgical and anesthetic management, postoperative complications remain a major concern and may affect patient recovery. Maintaining stable blood circulation during surgery is an important part of perioperative care. Terlipressin is a vasoactive medication that may help maintain blood pressure and improve hemodynamic stability during surgery. However, the relationship between intraoperative continuous terlipressin infusion and postoperative outcomes after laparoscopic hepatectomy remains unclear. This prospective observational cohort study aims to evaluate the association between continuous intraoperative terlipressin infusion and postoperative severe complications in patients undergoing laparoscopic hepatectomy. Patients undergoing laparoscopic hepatectomy at the First Affiliated Hospital of Sun Yat-sen University will be enrolled and followed according to a predefined study protocol. Perioperative clinical information, anesthetic management data, terlipressin exposure, and postoperative outcomes will be collected and analyzed. The primary outcome is the occurrence of severe postoperative complications, defined as Clavien-Dindo grade III or higher complications.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Adults aged 18 to 80 years * American Society of Anesthesiologists (ASA) physical status I-III * Scheduled for elective laparoscopic partial hepatectomy * Provided written informed consent Exclusion Criteria: * Inability to tolerate the planned surgical procedure based on pre-anesthetic assessment * Severe hepatic dysfunction (Child-Pugh class B or higher) * Severe renal dysfunction (blood urea nitrogen \> 9 mmol/L or serum creatinine \> 178 μmol/L) * Significant cardiovascular or cerebrovascular disease, including active coronary artery disease, severe valvular stenosis, hypertrophic obstructive cardiomyopathy, or history of extensive cerebral infarction * Known allergy to study medications * Body mass index (BMI) \> 35 kg/m² or \< 18 kg/m² * Hemoglobin level \< 90 g/L * Pregnancy or lactation * Participation in another clinical trial within the preceding 3 months * Any other condition considered inappropriate for study participation by the investigator
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07719933